胸腺肽α_1联合培美曲塞治疗老年晚期肺腺癌患者的临床研究

Clinical Study of Thymosin α_1 Combined with Pemetrexed in the Treatment of Elderly Patients with Advanced Lung Adenocarcinoma

目的评价胸腺肽α1联合培美曲塞在老年晚期肺腺癌治疗中的作用。方法 56例老年晚期肺腺癌患者分为2组,观察组30例采用胸腺肽α1联合培美曲塞化疗,对照组26例采用培美曲塞单药化疗。比较观察2组治疗前后近期疗效、免疫功能、生活质量及不良反应变化。结果 2组近期疗效比较差异无统计学意义(P>0.05)。观察组患者治疗后CD4阳性T淋巴细胞、CD8阳性T淋巴细胞、CD4/CD8均高于治疗前,差异均有统计学意义(P均<0.05)。治疗后,观察组患者CD4阳性T淋巴细胞、CD8阳性T淋巴细胞、CD4/CD8均高于对照组,差异均有统计学意义(P均<0.05)。观察组治疗后生活质量提高率高于对照组,差异有统计学意义(P均<0.05)。2组骨髓抑制和消化道反应的发生率比较差异无统计学意义(P>0.05)。结论胸腺肽α1联合培美曲塞可以增强机体免疫力,提高生活质量,且患者耐受性良好。

Objective To evaluate the effects of thymosin α1 combined with pemetrexed in the treatment of eld- erly patients with advanced lung adenocarcinoma. Methods Fifty-six elderly patients with advanced lung adenocar- einoma were divided into the treatment group and the control group. Thirty patients in the treatment group received the therapy of thymosin α1 and pemetrexed, while 26 patients in the control group were only treated with peme- trexed. The short-time effect, immune function, quality of life and toxicities in the two groups were evaluated before and after treatment. Results There was no statistical significant difference in the response rate between the two groups （P 〉0.05）. In the treatment group, the CD4, CD8 and CD4/CD8 after the treatment were higher than those before the treatment （P 〈 0.05 ）. After the treatment, the CD4, CD8 and CD4/CD8 in the treatment group were higher than those in the control group （ P 〈 0.05 ）. The improvement rate of quality of life in the treatment group was higher than that in the control group （P 〈 0.05 ）. There was no statistical significant difference in the marrow sup- pression and gastrointestinal reaction incidences between the two groups （ P 〉 0.05 ）. Conclusion For the elderly patients with advanced lung adenocarcinoma, thymosin α1combined with pemetrexed can enhance the immunologi- cal function, improve the quality of life and be well tolerated,